[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific’s Valuation: Assessing the Impact of Its $1 Billion Vaxcyte Vaccine Manufacturing Deal",
    "summary": "Thermo Fisher Scientific (TMO) shares are in focus after the company announced a multi-year manufacturing agreement with Vaxcyte that could be worth up to $1 billion. This deal further expands Thermo Fisher’s role in vaccine supply for the United States. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s multi-year manufacturing deal with Vaxcyte appears to have reignited enthusiasm among investors, driving an 11% share price gain over the past week and building...",
    "url": "https://finnhub.io/api/news?id=be9d19beeafecec7d264e5350cdf18dc6e6313893d15a2ae364705badd47cd58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759950373,
      "headline": "Thermo Fisher Scientific’s Valuation: Assessing the Impact of Its $1 Billion Vaxcyte Vaccine Manufacturing Deal",
      "id": 137028310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific (TMO) shares are in focus after the company announced a multi-year manufacturing agreement with Vaxcyte that could be worth up to $1 billion. This deal further expands Thermo Fisher’s role in vaccine supply for the United States. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s multi-year manufacturing deal with Vaxcyte appears to have reignited enthusiasm among investors, driving an 11% share price gain over the past week and building...",
      "url": "https://finnhub.io/api/news?id=be9d19beeafecec7d264e5350cdf18dc6e6313893d15a2ae364705badd47cd58"
    }
  },
  {
    "ts": null,
    "headline": "Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™",
    "summary": "Advancements in healthcare expenditure, research investment, and regenerative medicine are fueling growth while storage logistics remain a critical challengeDelray Beach, FL,, Oct. 08, 2025 (GLOBE NEWSWIRE) -- formation, and contamination risks threaten sample viability. Ensuring consistent global transportation standards will be a key differentiator for market leaders, particularly as demand for international collaboration and sample sharing increases. Request Sample Pages : https://www.markets",
    "url": "https://finnhub.io/api/news?id=a433b24e4a56387ab20bcaa0fdf0456d64f32c3306d62e9e823d40df66ac3b4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759935600,
      "headline": "Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™",
      "id": 137010959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Advancements in healthcare expenditure, research investment, and regenerative medicine are fueling growth while storage logistics remain a critical challengeDelray Beach, FL,, Oct. 08, 2025 (GLOBE NEWSWIRE) -- formation, and contamination risks threaten sample viability. Ensuring consistent global transportation standards will be a key differentiator for market leaders, particularly as demand for international collaboration and sample sharing increases. Request Sample Pages : https://www.markets",
      "url": "https://finnhub.io/api/news?id=a433b24e4a56387ab20bcaa0fdf0456d64f32c3306d62e9e823d40df66ac3b4e"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)",
    "summary": "Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks with high potential. In a report released on October 3, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) and set a price target of $134.00. In other news, Vaxcyte, Inc. (NASDAQ:PCVX) reported on September 30 that it entered […]",
    "url": "https://finnhub.io/api/news?id=36241b9b05d1ed404216618a5a6d3bf94be7b042600e376a67cb6207ba3c523d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759899424,
      "headline": "Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX)",
      "id": 137008024,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best biotech stocks with high potential. In a report released on October 3, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX) and set a price target of $134.00. In other news, Vaxcyte, Inc. (NASDAQ:PCVX) reported on September 30 that it entered […]",
      "url": "https://finnhub.io/api/news?id=36241b9b05d1ed404216618a5a6d3bf94be7b042600e376a67cb6207ba3c523d"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Group Maintains Thermo Fisher Scientific (TMO) Outperform Recommendation",
    "summary": "Evercore ISI Group Maintains Thermo Fisher Scientific (TMO) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=1a96c14edf6cfa29ebc771f61e220d43c7f66a2ba28bd4d270a12e9498d848aa",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759881968,
      "headline": "Evercore ISI Group Maintains Thermo Fisher Scientific (TMO) Outperform Recommendation",
      "id": 137005011,
      "image": "",
      "related": "TMO",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1a96c14edf6cfa29ebc771f61e220d43c7f66a2ba28bd4d270a12e9498d848aa"
    }
  }
]